Literature DB >> 28054307

Etiology and complications of thrombocytopenia in hospitalized medical patients.

Eric M Fountain1,2, Gowthami M Arepally3,4.   

Abstract

To determine incidence, risk factors, hematologic complications, and prognostic significance of thrombocytopenia in the general medicine population, we performed a single-institutional, retrospective study of all adult patients admitted to a general medical ward from January 1st, 2014 to December 31st, 2014 with hospital-acquired thrombocytopenia. Those with moderate thrombocytopenia, defined as a platelet count nadir of <100 × 10^9/L and/or a >50% relative decline, were compared to those with less severe thrombocytopenia. Of the 7420 patients admitted, 465 (6.3%) developed hospital-acquired thrombocytopenia. Infection and moderate thrombocytopenia were present in 56 and 23%, respectively. Severe sepsis and antibiotic use were both associated with moderate thrombocytopenia, and proton pump inhibitor use was statistically significant in both univariate and multivariate analysis. Hematologic complications were more frequent with moderate thrombocytopenia, including frequency of HIT testing and red blood cell transfusions. Outcome metrics including transfer to an intensive care unit (OR 6.78), death during admission (OR 6.85), and length of stay (10.6 vs. 5.1 days) were all associated with moderate thrombocytopenia. Thrombocytopenia is associated with poor prognosis, and the association between moderate thrombocytopenia and proton pump inhibitor use is relatively novel and should be validated in prospective studies.

Entities:  

Keywords:  Critical illness; Heparin-induced thrombocytopenia; Hospital-acquired; Infections; Thrombocytopenia

Mesh:

Substances:

Year:  2017        PMID: 28054307     DOI: 10.1007/s11239-016-1467-8

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  30 in total

1.  Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings.

Authors:  G K Lo; D Juhl; T E Warkentin; C S Sigouin; P Eichler; A Greinacher
Journal:  J Thromb Haemost       Date:  2006-04       Impact factor: 5.824

Review 2.  Drug-induced immune thrombocytopenia.

Authors:  Richard H Aster; Daniel W Bougie
Journal:  N Engl J Med       Date:  2007-08-09       Impact factor: 91.245

Review 3.  Platelets and the innate immune system: mechanisms of bacterial-induced platelet activation.

Authors:  D Cox; S W Kerrigan; S P Watson
Journal:  J Thromb Haemost       Date:  2011-06       Impact factor: 5.824

4.  Posttransfusion purpura occurrence and potential risk factors among the inpatient US elderly, as recorded in large Medicare databases during 2011 through 2012.

Authors:  Mikhail Menis; Richard A Forshee; Steven A Anderson; Stephen McKean; Rahul Gondalia; Rob Warnock; Chris Johnson; Paul D Mintz; Christopher M Worrall; Jeffrey A Kelman; Hector S Izurieta
Journal:  Transfusion       Date:  2014-07-28       Impact factor: 3.157

5.  Etiology of thrombocytopenia in all patients treated with heparin products.

Authors:  Damian A Laber; Monte E Martin
Journal:  Eur J Haematol       Date:  2005-08       Impact factor: 2.997

6.  Thrombocytopenia in medical-surgical critically ill patients: prevalence, incidence, and risk factors.

Authors:  Mark A Crowther; Deborah J Cook; Maureen O Meade; Lauren E Griffith; Gordon H Guyatt; Donald M Arnold; Christian G Rabbat; William H Geerts; Theodore E Warkentin
Journal:  J Crit Care       Date:  2005-12       Impact factor: 3.425

7.  Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group.

Authors:  E P Vichinsky; L D Neumayr; A N Earles; R Williams; E T Lennette; D Dean; B Nickerson; E Orringer; V McKie; R Bellevue; C Daeschner; E A Manci
Journal:  N Engl J Med       Date:  2000-06-22       Impact factor: 91.245

8.  The prevalence of pantoprozole associated thrombocytopenia in a community hospital.

Authors:  Efrat Dotan; Randi Katz; Jason Bratcher; Carrie Wasserman; Michelene Liebman; Georgia Panagopoulos; Colette Spaccavento
Journal:  Expert Opin Pharmacother       Date:  2007-09       Impact factor: 3.889

9.  Pantoprazole-induced thrombocytopenia in patients with upper gastrointestinal bleeding.

Authors:  Emine Binnetoğlu; Erdem Akbal; Hacer Şen; Fahri Güneş; Gökhan Erbağ; Mehmet Aşık; Neslihan Bozkurt; Ayşegül Uludağ; Murat Tekin; Sati Zeynep Tekin
Journal:  Platelets       Date:  2014-02-10       Impact factor: 3.862

10.  Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin.

Authors:  Edelgard Lindhoff-Last; Roumen Nakov; Frank Misselwitz; Hans-Klaus Breddin; Rupert Bauersachs
Journal:  Br J Haematol       Date:  2002-09       Impact factor: 6.998

View more
  5 in total

1.  Immune Thrombocytopenia is Still the Commonest Diagnosis on Consultative Hematology.

Authors:  Ram V Nampoothiri; Charanpreet Singh; Deepesh Lad; Gaurav Prakash; Alka Khadwal; Neelam Varma; Pankaj Malhotra
Journal:  Indian J Hematol Blood Transfus       Date:  2018-12-13       Impact factor: 0.900

2.  Association of thrombocytopenia and infection in patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention.

Authors:  Litao Wang; Weijiang Su; Jinhua Xue; Xiao Gong; Yining Dai; Jiyan Chen; Ling Xue; Pengcheng He; Yuanhui Liu; Ning Tan
Journal:  BMC Cardiovasc Disord       Date:  2021-08-21       Impact factor: 2.298

3.  Intra-aortic balloon pumping and thrombocytopenia in patients with acute coronary syndrome : Incidence, risk factors, and prognosis.

Authors:  Z Sheng; H Zhao; H Yan; S Jiang; Y Guan; Y Zhang; L Song; C Liu; P Zhou; K Liu; J Liu; Y Tan
Journal:  Herz       Date:  2017-07-19       Impact factor: 1.443

4.  Prevalence and aetiology of moderate and severe thrombocytopenia in a tertiary and quaternary centre in KwaZulu-Natal.

Authors:  Ayanda G P Jali; Bongani B Nkambule
Journal:  Afr J Lab Med       Date:  2020-08-24

5.  Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry.

Authors:  Daniele Pastori; Emilia Antonucci; Francesco Violi; Gualtiero Palareti; Pasquale Pignatelli
Journal:  J Am Heart Assoc       Date:  2019-10-28       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.